Studies on solubility, bioavailability and hypoglycemic activity of gliclazide β-cyclodextrin complexes

International Journal of Pharmacology

Volumn 2, Issue 6, 2006, Pages 656-663

  Abou Auda, Hisham S ^a   Bawazir, Saleh A ^a   Asiri, Yousef A ^a   Gubara, Othman A ^a   AI Hadiya, Badraddin M ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Beagle dogs; Gliclazide; Hypoglycemia activity; Inclusion complex; Pharmacokinetics; CD

Indexed keywords

BETA CYCLODEXTRIN; GLIBENCLAMIDE; GLICLAZIDE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; CORRELATION ANALYSIS; CRYSTALLIZATION; DOG; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MIXTURE; DRUG SOLUBILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; MALE; NONHUMAN; PRECIPITATION;

EID: 33846985293     PISSN: 18117775     EISSN: 18125700     Source Type: Journal    
DOI: 10.3923/ijp.2006.656.663     Document Type: Article

References (11)

1. Aggarwal, S., P.N. Singh and B. Mishra, 2002. Studies on solubility and hypoglycemic activity of gliclazidebeta-cyclodextrin-hydroxyl propylmethylcellulose complexes. Pharmazie, 57: 191-193.
2. Chow, D.D. and A.H. Karara, 1986. Characterization, dissolution and bioavailability in rats of ibuprofen-3-cyclodextrin complex system. Int. J. Pharm., 28: 95-101.
3. Gillman, A.G., T.W. Rall and A.S. Nies et al., 1990. In Goodman and Gillman's: The pharmacological basis of therapeutics. 8th Edn. Pergamon. Maxwell House, New York, USA., pp: 1485-1486.
4. Guyot, M., F. Fawaz and J. Bildet, 1995. Physicochemical characterization and dissolution of norfloxacin-cyclodextrin inclusion compounds and PEG solid dispersions. Intl. J. Pharm., 46: 49-55.
5. Higuchi, T. and K.A. Connors, 1965. Phase solubility techniques. Adv. Anal. Chem., 4: 117-212.
6. Loftsson, T. and M.E. Brewster, 1996. Pharmaceutical applications of cyclodextrins. Drug solubilization and stabilization. J. Pharm. Sci., 85: 1017-1025.
7. Moyano, J.R., M.J. Aria-Blanco and J.M. Gines et al., 1997. Nuclear magnetic resonance investigations of the inclusion complexation of gliclazide with β-cyclodextrin. J. Pharm. Sci., 86: 72-75.
8. Ozkan, Y., T. Atay and N. Dikmen et al., 2000. Improvement of water solubility and in vitro dissolution rate of gliclazide by complexation with betacyclodextrin. Pharm. Acta Helv., 74: 365-370.
9. Plainer, K.J. and A.N. Brogden, 1993. Gliclazide: An update of its pharmacological properties and therapeutic efficacy in non-insulin dependent diabetes mellitus. Drugs, 46: 92-125.
10. Rajewski, RA. and V.J. Stella, 1996. Pharmaceutical applications of cyclodextrins, 2. In vivo drug delivery. J. Pharm. Sci., 85: 1142-1169.
11. Uekama, K., A. Fujise, F. Hirayama, M. Otagiri and K. Inaba, 1984. Improvement of dissolution characteristics and chemical stability of prostaglandin El by cyclodextrin complexation. Chem. Pharm. Bull., 32: 275-294.